University of Pennsylvania

RTI Surgical enrolls first patient in ADMIRE study to confirm safety and effectiveness of Cortiva® Allograft Dermis in breast reconstruction, using proprietary Tutoplast® Tissue Sterilization Process.

Vaping, even nicotine-free, immediately impairs blood flow in femoral artery and reduces oxygen uptake, according to a University of Pennsylvania MRI study. The findings suggest potential vascular disease risks from chronic use.

Robert F. Kennedy Jr. criticizes Ozempic, suggesting better nutrition could replace drugs like it. With potential HHS leadership, his views might influence policy, though direct drug approval reversal is not within HHS Secretary's power; FDA must initiate such actions based on safety, efficacy, or manufacturing issues.

Research at the University of Pennsylvania develops a new method for designing ionizable lipids in lipid nanoparticles (LNPs) to improve mRNA therapeutic delivery, potentially accelerating vaccine and treatment development for various diseases.

WEF identifies 12 cancer breakthroughs, including personalized cancer vaccines, AI-driven early detection, and repurposed drugs for prevention, potentially leading to new clinical laboratory tests and diagnostics.

TrialX partners with Let’s Win Pancreatic Cancer to enhance clinical trial accessibility for pancreatic cancer patients and caregivers, offering personalized trial matching and bilingual support.

Soligenix forms European Medical Advisory Board to guide Phase 3 study of HyBryte™ in CTCL, targeting enrollment of 80 patients in U.S. and Europe by end of 2024, with results expected in 2026.

Upadacitinib, a JAK inhibitor, showed efficacy in treating giant cell arteritis (GCA), enabling steroid withdrawal in a phase III trial. 46.4% of patients achieved clinical remission without rescue steroids, compared to 29.0% in the placebo group. Upadacitinib demonstrated a favorable benefit-risk profile and could become an oral alternative to tocilizumab if approved.

46 polygenic risk scores (PRSs) for coronary heart disease (CHD) with similar population-level performance produced discordant individual-level risk estimates, with 20% of participants having PRSs in both the top and bottom 5th percentile at least once. This variability suggests that CHD PRSs with similar population-level characteristics may not provide consistent individual risk estimates, emphasizing the need for refined statistical methods and strategies to communicate uncertainty in clinical implementation.